Literature DB >> 2621422

Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment.

A K Batta1, R Arora, G Salen, G S Tint, D Eskreis, S Katz.   

Abstract

We have studied the effect of ursodeoxycholic acid on the serum and urinary bile acids in seven patients with moderate to severe primary biliary cirrhosis. Bile acids were characterized by gas-liquid chromatography-mass spectrometry and quantified by capillary gas-liquid chromatography. Serum bile acids were elevated 26-fold over control values, with 2.2 times more cholic acid than chenodeoxycholic acid. Urinary bile acid output was elevated 22-fold over control values with a cholic acid:chenodeoxycholic acid ratio of 1.6. In addition, lithocholic acid, deoxycholic acid, ursodeoxycholic acid, 1 beta-hydroxycholic acid, 1 beta-hydroxydeoxycholic acid, and hyocholic acid were identified in both serum and urine; the proportions of the 1- and 6-hydroxylated bile acids were much higher in urine than in serum of the patients (32.1% versus 4.2%). Three months of placebo administration did not change the serum and urinary bile acid composition. In contrast, ursodeoxycholic acid feeding (12-15 mg/kg body weight per day) for 6 months resulted in a 25% decline in the total serum bile acid concentration from the pretreatment values. The proportion of ursodeoxycholic acid increased from 2.1 to 41.2% of total bile acids, so that total fasting serum endogenous bile acid levels decreased 62.4%. Ursodeoxycholic acid feeding substantially increased urinary bile acid output, with ursodeoxycholic acid comprising 58.1%. The proportion of 1- and 6- hydroxylated endogenous bile acids was reduced by 45.5% from pretreatment levels and approximately 4.5% of the urinary bile acids were omega-muricholic acid, 1 beta-hydroxyursodeoxycholic acid, and 21-hydroxyursodeoxycholic acid. These results demonstrate significant changes in the serum and urinary bile acid pattern in primary biliary cirrhosis during ursodeoxycholic acid treatment. The beneficial effect of ursodeoxycholic acid may be due to reduction of the hydroxylated derivatives of endogenous bile acids together with the appearance of hydroxylated derivatives of ursodeoxycholic acid or it may be due to displacement of the more hydrophobic endogenous bile acids by the hydrophilic ursodeoxycholic acid.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2621422

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  16 in total

1.  New directions in primary biliary cirrhosis.

Authors:  M C Bateson
Journal:  BMJ       Date:  1990-12-08

2.  Neonatal sepsis leads to early rise of rare serum bile acid tauro-omega-muricholic acid (TOMCA).

Authors:  Evelyn Zöhrer; Katharina Meinel; Günter Fauler; Victor Aguiriano Moser; Theresa Greimel; Joachim Zobl; Axel Schlagenhauf; Jörg Jahnel
Journal:  Pediatr Res       Date:  2018-05-23       Impact factor: 3.756

3.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

4.  Urinary 1 beta-hydroxyursodeoxycholic acid during ursodeoxycholic acid therapy.

Authors:  R Yamakawa; A Kimura; K Aoki; M Suzuki; R Mahara; M Tohma
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

5.  Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.

Authors:  R Saeki; H Ogino; S Kaneko; M Unoura; K Kobayashi
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

6.  Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method.

Authors:  Juan C García-Cañaveras; M Teresa Donato; José V Castell; Agustín Lahoz
Journal:  J Lipid Res       Date:  2012-07-19       Impact factor: 5.922

Review 7.  Ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  Jelena S Rudic; Goran Poropat; Miodrag N Krstic; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 8.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

9.  Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption.

Authors:  E Sehayek; J G Ono; S Shefer; L B Nguyen; N Wang; A K Batta; G Salen; J D Smith; A R Tall; J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.

Authors:  Y Nishigaki; H Ohnishi; H Moriwaki; Y Muto
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.